Retatrutide

What is Retatrutide?

Retatrutide (development code LY3437943) is a synthetic 39-amino-acid peptide with CAS registry number 2381089-83-2 and molecular formula C221H342N46O68. The pharmacological literature classifies it as a triple GLP-1, GIP and glucagon receptor agonist based on in vitro receptor studies. Nocap Research supplies it as a lyophilized reference material for laboratory research only.

Chemical Identity

Retatrutide, also identified by the development code LY3437943, is a synthetic peptide composed of 39 amino acids. It is catalogued under CAS registry number 2381089-83-2 and is described by the molecular formula C221H342N46O68, with a molecular weight of approximately 4731.4 g/mol calculated from that formula. In the pharmacological literature the molecule is classified as a triple receptor agonist, with reported activity at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. These are in vitro molecular characterizations and do not describe an effect in humans or animals. Nocap Research offers this compound solely as a reference material for in vitro laboratory investigation.

Specifications

Structure and Modifications

Retatrutide contains Aib residues at positions 2 and 20 and an alpha-methyl-leucine at position 13. The lysine at position 17 carries a lipid side chain built from a C20 fatty diacid joined through a gamma-glutamic acid and oligo(ethylene glycol) linker, and the C-terminal serine is amidated.

Published cryo-EM work has resolved the peptide bound to each of its three reported receptors, and liquid-phase synthesis routes for the full sequence have been described in the chemistry literature.

Physical Form, Handling, and Storage

The material is supplied as a lyophilized (freeze-dried) powder. As a laboratory reagent, lyophilized peptide is generally stored desiccated and protected from light, with long-term storage commonly at -20C or below and short-term working material at 2C to 8C. For laboratory work the powder is solubilized in a solvent chosen for the intended in vitro application. These notes describe general handling of the material as a research reagent. They are not instructions for use in humans or animals.

Purity and Certificate of Analysis

Every Nocap Research batch of Retatrutide is tested by an independent laboratory before it is listed. The current batch results are below, transcribed from the certificate of analysis. The full certificate, and a link to verify it directly with the lab, are one click away.

How Nocap Research tests every batch and how to read a certificate of analysis.

Selected Scientific Literature

The peer-reviewed papers below characterize Retatrutide at the level of chemistry, structure, synthesis or analytical method. These references describe scientific literature and are not evidence of safety or efficacy for use in humans or animals.

1. Li W et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024. Reports cryo-EM structures of the peptide bound to the GLP-1, GIP and glucagon receptors. PMID 39019866 DOI 10.1038/s41421-024-00700-0
2. Mao CY et al. A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide. Org Lett. 2026. Describes a liquid-phase chemical synthesis approach for the peptide. PMID 42224238 DOI 10.1021/acs.orglett.6c02001

Search PubMed for more Retatrutide literature

Retatrutide 10mg in the Catalog

Price, current stock and the batch certificate for Retatrutide 10mg are listed on its product page. An account is required to purchase.

View Retatrutide 10mg: price, stock and certificate of analysis

More in the Research Library